ESEARCH ON THE ROLE of phosphoinositides in cellular signaling accelerated significantly after Michell's seminal review' and has been expanding ever since. Metabolic studies on human platelets have been no exception to this trend. Two of the most important research fronts today for work on signal transduction in platelets concern the regulation of phosphoinositidase C (PIC; a phospholipase C), which has been reviewed extensively, and the factors governing the metabolism of 3-OH-phosphorylated phosphoinositides (3-PPIs), products of the action of phosphoinositide 3-kinases (PI 3-Ks). Research in the former area has led to a wealth of information on the regulation of increases in cytosolic Ca2+ and activation of protein kinase C promoting physiologic events such as secretion in response to stimuli such as thrombin, thromboxane AS, collagen, and platelet activating factor. Recent developments in the latter area, particularly with respect to the function(s) of 3-PPIs, are such that it is now possible to review a relatively coherent body of work on platelets and, hopefully, provide inspiration for additional experimental approaches. The focus of this review, therefore, will be on 3-PPIs and PI 3-Ks. Hopefully, it will be clear from the results to be described that PI 3-K activity plays a role in regulating an important platelet function, ie, aggregation, and is also, in turn, affected by this function. It is likely that PI 3-Ks are involved in other events in platelets and platelet progenitors as well. The structures of the 3-PPIs, which are quantitatively a minor subspecies of the phosphoinositide lipid family, along with those of the better-known isomers, are shown in Fig 1. The reader interested in additional information on 3-PPIs and PI 3-Ks in a variety of cell types should be alerted to two detailed and thoughtful surveys, in the tradition of Michell's review of 1975,' by Stephens et a12 and Fry.3 Activated platelets display cytoskeletal reorganization, secretion, and integrin-dependent events that, as noted above, increasing evidence links to alterations in the metabolism of inositol-containing species, including 3-PPIs. Platelets, being anucleate, offer a useful model system for dissecting connections among receptor occupancy, metabolism of inositides, and morphologic changes uncomplicated by variations due to protein synthesis. They also can be obtained in quantity, with a good degree of homogeneity of cell type, for metabolic studies. However, unfortunately, because of limited availability of fresh human platelets (protein degradation being a significant risk for outdated platelets), human plateBfood, Vol88, No 12 (December 151, 1996 pp 4401-4414 lets have not been the system of choice for enzyme purification, and most kinetic and regulatory studies have not been undertaken with purified platelet enzymes. Platelets also significantly frustrate any molecular biologist longing to examine the effects of altered protein expression on metabolic and morphologic events, studies that may be predicated on techniques that allow massive culturing of human megakaryocytes and induced spawning of platelets as well as gene knock-out studies with mice. In an attempt, ultimately, to address issues of 3-PPI regulation at the level of molecular biology, using sufficient numbers of cells for metabolic studies, we have undertaken some work with a leukemic cell line, CHRF-288, derived from megakaryoblasts. These cells, having morphologic and cytochemical features of megakaryoblasts and immature megakaryocytes, were described initially by Witte et a14 and suspension culturing was reported by Fugman et al.5 Unlike K562 or HEL, CHRF-288 cells do not express myeloid or erythroid markers. Platelet-like characteristics include a high degree of expression of the integrin aIhpJ, which is necessary for fibrinogen-linked platelet aggregation. For reasons yet to be defined, CHRF-288 cells in suspension do not aggregate in response to thrombin + fibrinogen, but they are responsive in other ways (including secretion) to thrombin and to some agonists that cause platelet aggregation. Experimental results with these and HEL cells will be reviewed here as well. However, the majority of work that will be described has been performed with intact or permeabilized platelets or platelet subfractions, rather than with purified components in reconstitution experiments, and is limited by this constraint. Nevertheless, even
lets have not been the system of choice for enzyme purification, and most kinetic and regulatory studies have not been undertaken with purified platelet enzymes. Platelets also significantly frustrate any molecular biologist longing to examine the effects of altered protein expression on metabolic and morphologic events, studies that may be predicated on techniques that allow massive culturing of human megakaryocytes and induced spawning of platelets as well as gene knock-out studies with mice. In an attempt, ultimately, to address issues of 3-PPI regulation at the level of molecular biology, using sufficient numbers of cells for metabolic studies, we have undertaken some work with a leukemic cell line, CHRF-288, derived from megakaryoblasts. These cells, having morphologic and cytochemical features of megakaryoblasts and immature megakaryocytes, were described initially by Witte et a14 and suspension culturing was reported by Fugman et al. 5 Unlike K562 or HEL, CHRF-288 cells do not express myeloid or erythroid markers. Platelet-like characteristics include a high degree of expression of the integrin aIhpJ, which is necessary for fibrinogen-linked platelet aggregation. For reasons yet to be defined, CHRF-288 cells in suspension do not aggregate in response to thrombin + fibrinogen, but they are responsive in other ways (including secretion) to thrombin and to some agonists that cause platelet aggregation. Experimental results with these and HEL cells will be reviewed here as well. However, the majority of work that will be described has been performed with intact or permeabilized platelets or platelet subfractions, rather than with purified components in reconstitution experiments, and is limited by this constraint. Nevertheless, even with such limitations, studies with platelets have afforded insights into stimulus-response coupling, with applications that go beyond platelets themselves.
SOME HISTORY
The identification via deacylation and high-performance liquid chromatography (HPLC) analysis of a new phosphorylated phosphoinositide was made by Whitman et The compound was characterized further' and was found to be a species phosphorylated by a detergent-inhibitable kinase at the D-3 hydroxy position of the inositol ring of phosphatidylinositol. Two additional members of this group were identified in chemotactic peptide (f-met-leu-phe)-stimulated neutrophils"" as PtdIns(3,4,5)P3 and PtdIns(3,4)P2. A distinctive aspect of these 3-PPIs is that they are very poor substrates for the PICs described to date."." That the 3-PPIs are of relevance to signaling events was implied by early findings that their synthesis [more specifically, that of PtdIns(3,4,5)P3 and PtdIns(3,4)P2] appears to be required in cells other than neutrophils and platelets for cell transformation or growth stimulation in response to mitogenic polyoma virus middle T antigen (mT) or platelet-derived growth factor (PDGF).13*14 In these cases, the responsible kinase, PI 3-K, is found complexed in a phosphotyrosine-dependent manner, via the phosphotyrosine-binding src-homology 2 (SH2) domains of a subunit of one form of PI 3-K, to mT/ pp60 c-src or to the receptor tyrosine kinase, PDGF-R, respectively. Of interest as well is the observation that the mT complex is associated with cytoskeletal focal contacts (the anchor points for actin stress fibers) and can be immunoprecipitated with anti-vinculin s e r~m . '~ Because cytoskeletal reorganization is one of the earliest changes observed in polyoma-infected cells or in neutrophils exposed to chemotactic peptide, a possible signaling target for the 3-PPIs has been thought to be the cytoskeleton. The platelet, of course, is another example of a cell that undergoes rapid reorganization of the cytoskeletal apparatus upon stimulation by physiologic agonists such as thrombin, even if a proliferative response is not possible. It therefore seemed worthwhile to test whether platelets were capable of generating 3-PPIs when stimulated.
ACCUMULATION OF 3-PPls IN PLATELETS AND RELATED CELL LINES
Platelets, indeed, form PtdIns(3,4)Pz in response to thromPlatelets also accumulate PtdIns(3,4,5)P3 ; furthermore, both PtdIns(3,4)P2 and PtdIns(3,4,5)P3 increase in response to the thromboxane receptor agonist U46619 or, in permeabilized platelets, GTPyS.I6 The use of an increase in 32P-and 3H-inositol-labeled PtdIns(3,4)P2 as an indication of a change in mass has been validated for U46619-stimulated platelets by mass measurements, and PtdIns(3,4)Pz has been found to have the same distinctive fatty acid profile as that of the other phosphoinositides. 20 The mass of RdIns(3,4,5)P3 that accumulates in platelets exposed to thrombin has not been quantified directly, but, based on the amount formed in equilibrium labeling experiments with 3zPl, one can estimate it to be about 1% of the resting mass bin. [16] [17] [18] [19] of PtdIns(4,5)P2 or 8 to 10 pmoVl0' platelets. Most of the experiments in our laboratory have been undertaken using platelets exposed to aspirin before washing to eliminate effects secondary to thromboxane A2 generation. The elevation in PtdIns(3,4,5)P3 precedes that in PtdIns(3,4)P2.'" ' ' x No significant changes in PtdIns(3)P are observed in intact platelets incubated with platelet agonists, and permeabilized platelets show only small increases in PtdIns(3)P, which are minor in comparison with the increases seen in the more highly phosphorylated 3-PPIs. Stimulation of 3-PPI accumulation can also be achieved with the thrombin receptor tethered ligand peptides, SFLLRNPNDKYEPF2' or SFLLRN," but it is not a consequence of PDGF secretion, because no form of PDGF is able to elicit this effect or to potentiate the effects of thr~mbin.'~ Other agonists tested thus far that increase 3-PPI accumulation in platelets are lysophosphatidic acid (LPA)26 and adenosine diphosphate (ADP).27 Each is effective, even when added to aspirin-treated platelets, although they are much weaker agonists than is thrombin. CHRF-288 cells also respond to thrombin receptor stimulation (thrombin or SFLLRN)28 or exposure to LPA or with rapid and highly transient accumulations of PtdIns(3,4,5)P3 and PtdIns(3,4)P2. Similarly, an erythroleukemic cell line (HEL) that shares some characteristics of platelets and megakaryocytes accumulates PtdIns(3,4)P2 in response to thr~mbin.~' ROUTES OF SYNTHESIS Routes for the synthesis and subsequent metabolism of the phosphoinositides are shown in Fig 2 where known and potential enzymatic activities are indicated by the solid arrows and broken arrows, respectively. PI 3-K activities capable of using PtdIns, PtdIns(4)P, and PtdIns(4,5)P2 have been described in fractionated p l a t e l e t~, 2~.~"~~ as has a PtdIns(3)P 4-kinase This 4-kinase activity, in contrast to previously described PtdIns 4-kinase activities, is inhibited by detergents such as Nonidet P-40 and is present in both pellet and cytosolic fractions from platelet homogenates, with the cytosolic entity having an apparent molecular weight of 150 k D . Unfortunately, the relative activities of PtdIns(4)P 3-kinase and PtdIns(3)P 4-kinase have not been compared under the same conditions. In addition, two forms of inositol polyphosphate 3-phosphatase in brain extracts have been described that have the unusual property of hydrolyzing both Ins( 1,3)P2 and PtdIn~(3)P,~' and two PtdIns(3,4,5)P3-hydrolyzing 5-phosphatases are present in platelet^.^^ However, thus far, no PtdIns(3,4)P2 5-kinase has been reported for any cell. This fact is important to consider when evaluating the potential pathways for synthesis of PtdIns(3,4,5)P3. Finally, PtdIns(3,5)P2, although separable from PtdIns(3,4)Pz and PtdIns(4,5)P2 on the HPLC systems used, has not been reported to accumulate in response to platelet agonists and we have not seen such changes.
There is at present some controversy in the literature about the routes by which PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are formed in stimulated cells. Stephens et a1," working with f-met-leu-phe-activated neutrophils, and Hawkins et ai," studying PDGF-stimulated Swiss 3T3 fibroblasts, have concluded that PtdIns(3,4,5)P3 is generated by PI 3-K acting Ptdlns (3,4,5)P, on ptdInS(4,5)Pz. They attributed the delayed generation of PtdIns(3,4)Pz either to 5-phosphatase-mediated hydrolysis of PtdIns(3,4,5)P3 or to direct action of PI 3-K on PtdIns(4)P, although the former route was favored on the grounds that such a 5-phosphatase exists and that PtdIns(3,4,5)P3 might be the true intracellular signal. Therefore, hydrolysis by 5- Fig 1. Phosphoinositide species in the platelet. In keeping with IUB/IUPAC-recommended abbreviations,'" Ptd refers to phosphatidyl, where sn 12-diacylglycerol is connected vie sn 3-OH of glycerol to C-l of myoinositol by a phosphodiester linkage; Ins refers to Dmyeinositol; and locants within parentheses refer to phosphorylation sites at OH-groups on the inositol ring. Unlike the case for, eg, adenosine phosphates, there is only one type of phosphorylatable structure (the OH species on the ring) in phosphoinositides, therefore Ptdlns(3,41P2 is correct, whereas Ptdlns(3',4')P2 is not, etc. The P of phosphate, according to IUB/IUPAC, should be rendered in italics, but this is not done here or in most publications. < phosphatase would therefore be a means of its disposal. In contrast, Cunningham et all9 and Cunningham and Majerus?' based on experiments with thrombin-stimulated platelets and PDGF-stimulated NIH 3T3 fibroblasts, respectively, reported PtdIns(3)P + PtdIns(3,4)Pz + PtdIns(3,4,5)P3 to be the route of synthesis. For the system in which there would seem to be an overlap between the two laboratories, ie, PDGF-stimulated 3T3 cells, there were several procedural differences. Hawkins et a137 used 16-hour serum-starved Swiss 3T3 cells that were labeled with 32Pi for 30 minutes before PDGF addition to be assured of nonequilibrium labeling of the major phosphoinositide species, with equilibrium being achieved after 70 minutes. Incubations were quenched with CHC13/MeOH. A time course study to monitor the appearance of labeled PtdIns(3,4,5)P3 and PtdIns(3,4)Pz in response to 30 ng/mL PDGF showed that PtdIns(3,4,5)P3 was formed very rapidly, achieving a maximum level within 60 seconds, whereas the appearance of PtdIns(3,4)Pz was delayed by about 20 seconds. Incubations with PDGF to generate products for digestive analysis were performed for 35 seconds. The products were rigorously identified. Because, under nonequilibrium labeling conditions, the hottest phosphate is the last phosphate added to the inositol ring, determinations of the specific activity of the phosphates in the various positions of the inositol ring yield information about which kinase is acting on which substrate. The analyses showed that the percentage of distribution of 32P in each position of PtdIns(3,4,5)P3 was #l = 0.45%; #3 = 41.3%; #4 = 26.0%; and #5 = 32.0%. Because PtdIns(4,5)Pz is 4 Ptdlns (4) P Ptdlns ( 4 3 ) P2 formed by 5-kinase acting on PtdIns(4)P and the phosphodiester (1) phosphate position would be labeled only slowly by de novo or by PI cycle (Fig 3, pathway 7 ) synthesis, one must conclude from these data that PI 3-K acts on PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Cunningham and Majerus3' used NIH 3T3 cells grown overnight in 0.5% fetal calf serum. The cells were washed and labeled with 32Pi for 60 minutes at 37°C. Incubations with 50 ng/mL PDGF were terminated after 5 minutes with 1N HCl. It was not reported how closely the 60-minute labeling period approached that for equilibrium, but if these cells are similar to Swiss 3T3 cells, one would expect equilibrium to be virtually achieved, and therefore minimal differences detectable for positions 3, 4, and 5. Nevertheless, positional labeling differences were observed. Time-course data for the production of PtdIns(3,4,5)P3 and PtdIns(3,4)P2 in 3T3 cells responding to PDGF were not provided in this study. Positional analyses of the phosphates on Ins(1,3,4,5)P4 derived from PtdIns(3,4,5)P3 yielded an average distribution in two experiments of #l = 2.5%; #3 = 24.5%; #4 = 31.5%; and #5 = 41.5%. One would conclude from these studies that PtdIns(3)P + Ptdlns(3,4)P2 + PtdIns(3,4,5)P3. The observations of Stephens et a l l 0 and Hawkins et a13' that the increases in labeled PtdIns(3,4,5)P3 precede those in labeled PtdIns(3,4)P2 and that labeled PtdIns(3)P does not increase significantly in the period preceding (or during) that in which PtdIns(3,4,5)P3 and PtdIns(3,4)P2 levels increase would both tend to favor the route of a stimulated PI 3-K acting on PtdIns(4,5)P2, and activation of PI 3-K showing substrate preference for PtdIns(4,5)P2 has been observed in several stimulated cell types. All of this would be difficult to reconcile with PtdIns(3)P 4-kinase activity using a cold, endogenous pool of PtdIns(3)P.
In light of the opposing conclusions about the route for synthesis of PtdIns(3,4,5)P3 [and PtdIns(3,4)P2] described above, we considered it important to re-examine the platelet system. Instead of incubating platelets for 60 minute^'^ with 32Pi (we and others have found that equilibrium labeling is achieved by 60 to 90 minutes), we have exposed platelets to high amounts of 32Pi for 10 minutes and incubated the platelets immediately with phosphate-free thrombin for 20 or 60 seconds, terminating the incubations with CHC13/MeOW For personal use only. on October 31, 2017. by guest www.bloodjournal.org From HCI, rather than with 1 m o m HCl and cooling." It is known that thrombin accelerates uptake of Pi by fivefold to 10-fold,39 and we reasoned that newly taken up 32Pi would have more of an impact on the 32P-ATF' pool of 10-minute than of 60-minute incubated platelets, thereby improving the likelihood of measuring positional differences. Upon resolution and processing of PtdIns(3,4,5)P3 and PtdIns(3,4)Pz and analysis of positional specific activities, we have found that, for both incubation periods, the order of 32P-spe~ifi~ activities in PtdIns(3,4,5)P3 is #3 > #5 > #4 S # l and in PtdIns(3,4)P2 is #3 > #4 B #l."
Our data are thus consistent with PtdIns(4,5)P2 being the initial, if not the sole [since we cannot distinguish 5-phosphatase-mediated breakdown of PtdIns(3,4,5)P3 from PI 3-K action on PtdIns(4)PI substrate for PI 3-K in thrombin-stimulated platelets, as is true for f-met-leu-phe-activated neutrophils and PDGF-activated Swiss 3T3 fibroblasts. These results are summarized in Fig 3 (pathways 1, 2 , and 4). The route of synthesis is obviously an important issue for consideration of regulatory factors for 3-PPI generation in the platelet and other cells; hopefully, a resolution of these disparate findings will occur soon.
REGULATION OF 3-PPI ACCUMULATION IN PLATELETS AND CHRF-288 CELLS
Localization of Pi 3-Ks. When platelets are lysed by sonication, PI 3-K activity is found in both particulate and cytosolic fractions.32 However, a dissection of this system with regard to Triton-solubility indicates that PI 3-K activity becomes more localized to the cytoskeleton after platelet a~tivation.~' These studies are based on the observation that most platelet proteins, except for actin filaments and those proteins associated with actin filaments, are soluble in 1% Triton X-100.40 A portion of the actin filaments, linked with the membrane ~keleton,4',~' is sedimentable from Tritonlysed resting platelets at low g forces (15,600g for 4 minutes), whereas most of the membrane skeleton, containing short actin filaments linked to spectrin-rich lamina under the plasma membrane sediments at 100,OOOg for 3 hours. As actin polymerization increases shortly after platelet activation by thrombin, most of the cytoskeleton, including the membrane skeleton, becomes sedimentable from l % Triton X-l00 platelet lysates at low g forces. Actin polymerization can be inhibited efficiently by cytochalasin but depolymerization of the actin associated with the membrane skeleton is achieved by exposure of Triton lysates to DNAse 1 : ' which binds stoichiometrically to monomeric actin." These tools have enabled us to distinguish the newly polymerized cytoskeletal matrix from the membrane skeleton as possible sites for attachment of PI 3-K.
We have measured PI 3-K activity in both Triton-soluble (after removal of inhibitory Triton) and Triton-insoluble platelet extracts, as well as PI 3-K assayed by Western blotting of the a-and &p85 subunits of PI 3-K.27*31 The best known PI 3-K, here designated p85/PI 3-K, has been found to be a heterodimer consisting of 85-kD and 110-kD subu n i t~. '~. '~ The p85 subunit, which contains two SH2 domains and one SH3 domain, but does not have kinase activity, is known to have two major forms, a and p. Alternatively spliced, smaller forms of p85, eg, p85/AS53, have also been reported to be present in muscle and brain!'
Western blots with antibodies to the a-p85 subunit and the p-p85 subunit have shown that the a-p85 subunit is the more abundant isoform detectable in human platelet preparation^."^'^*^' The 110-kD subunit contains the PI 3-K catalytic activity and, curiously, a serine-directed protein kinase activity that can phosphorylate the p85 subunit, resulting in inhibition of p85/ PI 3-K activity.& Antibodies to the a + &p85 subunits immunoprecipitate PI 3-K activity due to the associated p1 10 subunits. Although in resting platelets most PI 3-K is Tritonsoluble, a small amount of p85PI 3-K is associated with the cyt~skeleton.~'~~~ In the activated platelet, more p85/PI 3-K (both a and p) shifts to the cytoskeleton and is sedimentable in Triton buffers at 15,OOOg for 4 minutes. This cytoskeletal PI 3-K is more active (enzymatic activity/immune-quantifiable enzyme) than either the resting or activated-platelet PI 3-K that remains Triton-soluble. Interference by cytochalasin D with actin polymerization does not block the association of PI 3-K (detected by Westem blot or activity) with the activated platelet cytoskeleton; however, treatment of the Triton lysate with DNAse I strongly decreases the Tritoninsolubility of PI 3-K (as well as actin). We have concluded, therefore, that activated PI 3-K is associated with a component of the membrane skeleton, rather than with newly polymerized actin. We have observed as well that interference by arg-gly-asp-ser (RGDS) with fibrinogen binding to (~I I b p 3 impairs recruitment of p85PI 3-K to the cytoskeleton, implying a role for integrin in at least part of this process. Additional components of the membrane skeleton in the activated platelet include p60' "" (a tyrosine kinase that itself becomes tyrosine-phosphorylated and more active47), allbp3, vinculin, a-PKC, and E-PKC.*~.~' It has also been reported that thrombin induces an association of p85PI 3-K with p60""" and p6@ (another, related, tyrosine kinase) in platel et s!'
Because these studies were performed by immunoprecipitating phospho-tyrosine and srclfyn-containing proteins from centrifugally clarified detergent lysates of platelets, it is most likely that (1) the bulk of activated PI 3-K activity had already been removed during centrifugation, which would sediment most of the cytoskeleton and leave smaller complexes in the supernatant; and (2) several components were present in the immunoprecipitates, including not only the two tyrosine-phosphorylated entities (p6@-"" and p6@) and PI 3-K, but also other proteins associated with a light cytoskeletal matrix. Thus, it is not possible to conclude from these data that PI 3-K is bound directly to either tyrosine kinase(s) or a tyrosine-phosphorylated protein or that PI 3-K is itself tyrosine-phosphorylated. Other data, in fact, indicate that p85 of PI 3-K is not phosphorylated at tyrosine in activated platelets. Determinations of the direct binding site(s) for p85PI 3-K at the membrane skeleton and the mechanism of initial PI 3-K activation await further studies. Some additional information relevant to the possible mechanism of these events is provided by studies from Shibasaki et a14' and Guinebault et al. " The former lab has observed that p85PI 3-K binds to a-actinin (present in platelet cytoskeleton, cross-linking actin) via the p85-subunit, and the latter group has reported that p85PI 3-K can be activated For personal use only. on October 31, 2017. by guest www.bloodjournal.org From directly by interactions between the SH3 domain of p85 and a proline-rich region of ~1 2 5 '~~. FAK (focal adhesion kinase) is a tyrosine kinase that localizes with integrins at the cytoskeleton via a C-proximal focal adhesion targeting (FAT) sequence and an N-proximal sequence that binds to the cytoplasmic domains of P -i n t e g r i n~.~~ In platelets, activation (and tyrosine-phosphorylation) of FAK is stimulated by integrin cross-linking in a manner dependent on PKC activation." Another candidate for p85PI 3-K targeting is the tyrosine kinase p 7 P k , which is activated and tyrosinephosphorylated in platelets that are exposed to thrombin, collagen, TXAz, or the low-affinity Fcy receptor ( F C~R I I A ) . *~-~~ A portion of ~7 2 "~' activation is insensitive to blockage of integrin function, but much of ~7 2 " ' is phosphorylatedlactivated soon after agonist-induced or anti-LIBS Fab-induced binding of fibrinogen to a[&." Syk is also recruited to the cytoskeleton after thrombin-induced platelet activation'' and could thus participate in postintegrin as well as preintegrin signaling. This tyrosine kinase itself contains three potential phosphorylation sites in the YXXM motifs known to be consensus binding sites for SH2 domains of p85/PI 3-K,s6 and p85/PI 3-K has been found in the immunoprecipitated activated FcyRIIA receptor containing A clear route for the activation of p85/PI 3-K in the time that precedes receptor or integrin clustering has not yet been defined, but it seems likely to involve protein kinase C and small GTP-binding proteins (see below) and may involve tyrosine phosphorylations that are independent of integrin occupancy.
In addition to stimulation of platelets via the thrombin receptor (which leads to activation of (YI& and aggregation), stimulation of the adhesion receptor GPIb/IX by von Willebrand factor (vWF) leads to increased localization of p85/PI 3-K as well as tyrosine kinase pp60~"" and (judging by the mobility of tyrosine-phosphorylated proteins indicated) possibly p7Yyk at the cytoskeleton in an a,&-independent manner.'* Such recruitment is unaffected by exposure of the platelets to aspirin (and therefore prevention of TXA2 formation), although aspirin abolishes vWF-induced dense granule (and presumably ADP) secretion and phosphorylation of p47 (ie, pleckstrin, a target of protein kinase C activity). However, as is true for FcyRIIA activation, it has not been reported whether vWF/ristocetin per se actually causes an increase in the levels of PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2 in intact platelets.
Recently, a new form of PI 3-K has been described after cloning and expression studies.59 The molecular weight of this catalytic species (p1 107) is also approximately 1 10 k D , but it lacks a binding site for p85 subunits and, instead, contains an N-terminal pleckstrin homology (PH) domain. Most interestingly, it is activated by P y subunits of heterotrimeric G-proteins. Using reverse transcriptase-polymerase chain reaction and degenerate oligonucleotide primers to the kinase domain of p110 catalytic subunits of PI 3-K, we have detected p1 1Oy in CHRF-288 mRNA (Rittenhouse and Volinia, unpublished results). fly-activatable PI 3-K activity and immunoreactive p1 1Oy have been observed for human neutrophils,6' platelet^,^"" and CHRF-288 cells,2x and PI 3-K y has been purified from porcine platelet lysates." We have observed that both immunologically detectable and Pyactivatable PI 3-K (designated P1 3-Ky) appears in the cytoskeleton of thrombin-stimulated platelet^'^.'' and is not present in the cytoskeleton of resting platelets. Under resting conditions, it is Triton-soluble and not immunoprecipitated by antibodies to a-p85 or P-p85. Activated PI 3-Ky is associated with P y , and its activity can be inhibited by binding f l y with the PH domain-containing C-terminal peptide of a &adrenergic receptor kinase (PARK-PH) lacking protein kinase a~tivity.".~' Like p85/PI 3-K, PI 3-Ky uses all three phosphoinositide substrates but displays a preference for PtdIns(4,5)P2 .h2.h ' Because activated PI 3-Ks localize to the membrane skeleton, the products of PI 3-K activity should also be localized in membrane skeleton-proximal regions of the plasma membrane. Thus, a 3-PPI such as PtdIns(3,4,5)P3 would be concentrated in a position with increased potential for affecting cytoskeletal organization at membrane linkages, perhaps by modifying a nearby enzyme activity. This is, at least, consistent with the possibility that PtdIns(3,4,5)P3 [and PtdIns(3,4)P2?] act in part to affect cytoskeletal organization.
Role of PKC. The increase in 3-PPI levels that follows activation of the thrombin receptor does not seem to be simply a consequence of PKC activation and/or Ca" mobilization, ie, the activation of PIC (see Fig 3, pathway 6 ) is not sufficient cause for the full response. 0-Phorbol dibutyrate or P-phorbol myristate acetate (P-PMA), alone or together with Ca" ionophore, at concentrations that stimulate PKC activity and [Ca"] increases equivalent to those achieved by thrombin, does not produce a similar elevation of 3-PPI levels. Nevertheless, PKC stimulation does play a necessary role in the process. Permeabilized platelets exposed to the pseudosubstrate peptide inhibitor of PKC, RFARKGALR-QKNV, show inhibited accumulation of 3-PPIs in response either to thrombin or GTPyS, although this inhibitor does not affect the activity of purified PI 3-K." Furthermore, only the PKC-activating p-isoform of PMA stimulates 3-PPI accumulation, and activation of platelets with 0-PMA causes a shift of a-and P-p85/PI 3-K to the cyt~skeleton.~' In contrast, PI 3-Ky activity does not increase in the cytoskeleton of P-PMA-activated platelets. Thus, a portion (that which is due to p85/PI 3-K) of the 3-PPI response to agonists such as thrombin seems likely to be dependent on PKC activity (Fig 4) . Of potential relevance here, 0-PMA also rapidly stimulates tyrosine phosphorylation in human platelets, although the identities of the tyrosine kinases activated are not clear.64
Role ~f a , ,~f l~. There is also a role for the platelet integrin a& in modulating the accumulation of PtdIns(3,4)P2 in response to thrombin.".6s This is the species that appears relatively later than PtdIns(3,4,5)P3. Inhibition (>80%) of fibrinogen binding to platelet integrin by RGDS inhibits by 40% to 50% the late (5 minutes) thrombin-induced increases in PtdIns(3,4)P2, and a similar effect is achieved by omitting Ca2' from the medium or when platelets from thrombasthenic (al&-deficient) patients are incubated with thrombin. However, RGDS does not inhibit 3-PPI accumulation in platelets exposed to P-PMA,'7 implying that the activation of PI 3-K by PKC is not secondary to fibrinogen binding. 
F i b , fibrinogen; MR-R, thrombin receptor; PKC, protein kinase C(s).
Normal platelets and thrombasthenic platelets, when permeabilized in the presence of 0.1 mmol/L Ca2+ and exposed to thrombin or GTPyS, moreover, form similar amounts of Ptdh(3,4)P2 and PtdIns(3,4,5)P3, as do intact platelets exposed to thrombin in the absence of added Ca2+.= These are conditions in which am& is not activated. Furthermore, the accumulation of PtdIns(3,4,5)P3 and PtdIns(3,4)P2 induced by exposure of platelets to LPA for 60 seconds is not affected by the presence of the disintegrin eristostatin, which very effectively blocks platelet aggregation?6 Platelet integrin may thus modulate the activity of a PtdIns(3,4)P2 phosphatase, PtdIns(3)P bkinase, and/or a PI 3-K, but is not necessary for the initial activation of PI 3-K. An effect on PtdIns(3,4,5)P3 5-phosphatase is not a sufficient explanation, because PtdIns(3,4,5)P3 accumulations do not appear to be increased by such treatments?' Interestingly, aggregation of platelets by thrombin leads to the dissociation of PtdIns(3,4,5)P3 5-phosphatase from p85PI 3-K at the plateFor personal use only. on October 31, 2017. by guest www.bloodjournal.org From let cytoskeleton.'6 Were the activity of this phosphatase a determining factor, one might have predicted that aggregation would lead to less formation of PtdIns(3,4)P2, rather than more. Obviously, this indicates that we cannot be sure how much of a predictor the cytoskeletal localization of catabolizing enzymes is with respect to 3-PPI accumulations, but it would appear that factors in addition to 5-phosphatase affect PtdIns(3,4)P2 levels.
Conflicting findings have been published about the ability of fibrinogen binding to a& (and of platelet aggregation) to activate 3-PPI accumulation (ie, outside-in signaling) in the absence of the participation of another signal, such as stimulation of PKC by TXA2 or ADP. Kovacsovics et a167 have reported that promoting fibrinogen binding to all& induced by an a&-directed antibody Fab fragment (ligandinduced binding site via anti-LIBS-Fab) leads to a dramatic increase in platelet PtdIns(3,4)P2 levels. In contrast, we have observed only a small (2X) change in the amount of platelet PtdIns(3,4)P2 after exposure to LIBS-Fab + fibrinogen, no change in PtdIns(3,4,5)P3, and a small (1.4X) increase in PtdIn~(4,5)P~.'~ Thrombin receptor stimulation can cause up to a 20X increase in PtdIns(3,4)P2 that is 50% inhibitable by blocking fibrinogen binding.2' An explanation for the discrepancy between the findings from the two labs may lie in our use of aspirin and apyrase or CP/CPK to block the receptor-activating effects of cyclooxygenase products (eg, TXA2) and ADP, respectively, whereas the results of Kovacsovics et alh7 may include the potentiating effects of TXA2 + ADP. ADP can cause a 2X increase in PtdIn~(3,4)P,,'~ and the activating effects of TXA2 analogues have been described.",*" We suspect that, as is true for the tyrosine-phosphorylation of p7Tyk " and p125FAK,51.68 binding of fibrinogen by platelets is a necessary but not sufficient condition for the full response of PtdIns(3,4)P2 accumulation.
Role of GTP-binding proteins. The implication of the stimulatory effects of GTPyS (but not of GDPPS) is that 3-PPI accumulation is under the control GTP-binding protein(s)." If there is one major G-protein responsible for the changes seen, it is apparently not of the G, subclass that regulates adenylyl cyclase, because inactivation of G, by pertussis toxin treatment causes only a minor inhibition of 3-PPI accumulation." Similarly, epinephrine, although able to activate Gi via the a2 adrenergic receptor, is neither able to stimulate significant increases in 3-PPIs or potentiate increases in 3-PPIs in conjunction with phorbol diester and Ca2+ ionophore." One is still left with a wide variety of potential G-protein candidates for this regulatory function, including G,, G,, and G, in the heterotrimeric class, as well as a full palette of small G proteins. Indeed, both small and heterotrimeric G-proteins (including Gi) are involved in regulating PI 3-K activation, as will be discussed below.
In the context of cytoskeletal reorganization, increasing attention has focused on the small GTP-binding protein Rho. Rho has been found to regulate the assembly of actin stress fibers and focal adhesions (sites of cytoskeletal interaction with the plasma membrane, bearing some similarity to cytoskeletally associated alIbp3") in growth factor-stimulated fib rob last^.^' Such assembly is blocked if Rho is ADP-ribosylated by the exoenzyme C3 transferase from Clostridium botulinum, and the blockage can be overcome by the injection of Rho. Because we have shown that the accumulation of 3-PPIs in permeabilized platelets appears to be under the control of GTP-binding protein(s) other than or in addition to and because RhoA is present in platelets and is the sole substrate ADP-ribosylated by C3 tran~ferase,~' which inhibits thrombin-stimulated platelet aggregati~n,~' we tested whether Rho participates in regulating platelet PI 3-K. Such a target would provide a potential mechanism for the effects of Rho on cytoskeletal changes.
In examining cytoskeletal preparations from control and thrombin-activated platelets, we have found that most of Rho is Triton-soluble in platelet controls, but the amount of Rho in the cytoskeletal fraction increases threefold to fourfold within 45 seconds of platelet exposure to thrombin. 32 We have also prepared soluble fractions from unstimulated platelets and have been able to activate PI 3-K with GTPyS, but not GDPPS, in these preparation^.".^' The activation is blocked by C3 transferase-catalyzed ADP-ribosylation of Rho and rescued by the addition of recombinant exogenous Rho expressed in and isolated from a bacterial host. Therefore, Rho does not need to be posttranslationally modified. Similarly, we have found that GTPyS-stimulated PI 3-K activity in lysates of CHRF-288 cells also is inhibited by ADP-ribosylation of Rho.IX C3 transferase enters healthy platelets and ADP-ribosylates platelet Rho rather poorly.
Some improvement is achieved if platelets are stressed by cold and exposure to Tris buffer,72 but these are not optimal conditions for examining stimulated 3-PPI accumulation in platelets. Therefore, we have studied permeabilized platelets instead. C3 transferase or another Rho-ADP-ribosylating enzyme, EDIN, also partially inhibits the activation of PI 3-K in thrombin receptoror GTPyS-stimulated platelets." In contrast with findings for some other cells,74 ADP-ribosylation of Rho does not affect "P-labeling of platelet Ptdlns(4,5)P2, nor does GTPyS or ADP-ribosylation of Rho in platelet lysates affect PtdIns(4)P 5-kinase activity."~" Platelets may thus lack significant amounts of a Rho-susceptible isoform of PtdIns(4)P 5-kinase. We have concluded that platelet PI 3-K is activated. directly or indirectly, by RhoA. One argument in support of the direct route has been that PI 3-K possesses on its p85 subunit not only the SH2 and SH3 domains shared by a variety of proteins, including PIC and GTPase-activating proteins (GAPS), but also the rho/GAP-like domain that has been shown to be necessary for the GTPase-activating functions of ~~o / G A P .~' However, studies designed to evaluate the direct interaction between Rho and PI 3-K have indicated no direct binding of Rho to recombinant p85 or activation of recombinant p85/PI 3-K a~tivity.~' Because Rho is immunoprecipitated from platelet cytosol by p85/PI 3-K-directed antibodies, we suspect that some sort of complex is present involving molecules in addition to p85/PI 3-K and Rho; this possibility is under study. Furthermore, it seems likely that activation of Rho is downstream of PKC activation. Stimulation of p85PI 3-K activity by exposure of platelets to p -PMA is inhibited partially by ADP-ribosylation of Rho.27 This finding is consistent with the observations of Tominaga et al,77 who have reported that LFA-l-dependent lymphoFor personal use only. on October 31, 2017. by guest www.bloodjournal.org From cyte aggregation induced by PMA can be inhibited by ADPribosylation of Rho. Thus, two possibly related events downstream of Rho, ie, p85PI 3-K activation and aggregation, appear to be dependent on PKC activity (Fig 4) . The correlation of p85/PI 3-K activation with platelet aggregation will be addressed more directly later in this review.
Whereas Rho participates in the regulation of p85PI 3-K activity, it does not alter the activity of PI 3 -K~. 3~ Instead, this form of PI 3-K is activated by the P y subunits of heterotrimeric G-proteins (Fig 4) . Such Py subunits dissociate from a subunits when seven-transmembrane domain receptors, such as the thrombin receptor, are occupied by the appropriate ligand. It is now known that the thrombin receptor can activate at least two types of heterotrimeric G-protein: Gi and Gqi2.78-80 We have observed, as noted earlier, that binding of P y by exogenous PARK-PH prevents activation of PI 3-Ky in platelet cytoskeletal fractions or supernat a n t~. '~,~~ When added to permeabilized platelets, PARK-PH inhibits a portion of thrombin receptor-stimulated 3-PPI accumulation.33 Approximately 60% of thrombin receptoractivated 3-PPI accumulation is attributable to PI 3-Ky, with the remainder apparently a result of Rho-dependent p85PI 3-K activation."
Role of pleckstrin. One of the earliest events observed to follow platelet (and PKC) activation in response to a variety of agonists is the phosphorylation of pleckstrin (also designated p40 or p47). Pleckstrin is a cytosolic protein that contains two different PH domains separated by a 150-residue ~e p t i d e .~' .~~
The phosphorylation sites are at Seri13, Thr'I4, and Ser'I7 of the interdomain PH domains have been reported to interact both with PtdIns(4,5)P2 and PY."~' We have examined the effects of recombinant and endogenous pleckstrins on platelet PI 3-Ky and p85PI 3-K activities and found that, depending on its phosphorylation/ charged state, pleckstrin inhibits PI 3-Ky but not p85PI 3-K.63 Phospho-pleckstrin-mediated inhibition of PI 3-Ky is overcome by excess P y and is restricted to PtdIns(4,5)P2 as substrate, ie, pleckstrin does not inhibit phosphorylation of PtdIns(4)P or PtdIns by PI 3-KyF3 It thus seems likely that an interaction of phospho-pleckstrin with PtdIns(4,5)P2 promotes the binding of P y by phospho-pleckstrin. Consistent with this, activation of PKC by exposure of platelets to P-PMA before lysis (to increase endogenous pleckstrin phosphorylation) causes inhibition of soluble p y-stimulatable PI 3-K activity only when assayed with PtdIns(4,5)Pz substrate. As noted above for purified PI 3-Ky and exogenous phospho-pleckstrin, inhibition is overcome by increasing concentrations of ,By. Furthermore, we have observed that brief treatment of platelets with P-PMA before exposure to the thrombin receptor agonist SFLLRN selectively inhibits PI 3-Ky activity in intact platelekB8 As will be seen below, this appears to constitute a form of feedback inhibition (Fig  4) , because 3-PPI, like PIC-generated diacylglycerol (Figs 3  and 4) , can promote pleckstrin phosphorylation by stimulating protein kinase a~t i v i t y .~~,~~* " This is, in a way, analogous to another feedback phenomenon recently proposed:' based on experiments in which p85PI 3-K association with a tyrosine-phosphorylated membrane receptor (and therefore, presumably, access to substrate) was inhibited by PtdIns(3,4,5)P3 through competition of PtdIns(3,4,5)P3 for the SH2 domains of p85. However, it is not clear whether a feedback event like this for p85/PI 3-K occurs in platelets. It is also not known whether p8WI 3-K activity in platelets in vivo is regulated by the interaction of p85/SH2s with phospho-tyrosines.
EFFECTS OF PI 3-K ACTIVATION AND 3-PPIs
Phosphorylation of pleckstrin. We and others have reported that the phosphorylation of pleckstrin is partially dependent on PI 3-K.24*90 Pleckstrin phosphorylation in response to thrombin receptor stimulation is progressively susceptible to inhibition by wortmannin, a potent and specific inhibitor of platelet PI 3-Ks (both p85PI 3-K and PI 3-Ky), blocking both the lipid kinase and intrinsic protein kinase activities of this enzyme (see below). Wortmannin achieves 50% to 60% inhibition of pleckstrin phosphorylation 60 seconds after exposure of platelets to SFLLRN, whereas pleckstrin phosphorylation reaches maximum levels within 10 seconds of exposure to SFLLRN. PI 3-K thus seems to play a gradually increasing role in promoting pleckstrin phosphorylation. The ICso for wortmannin in inhibiting SFLLRN-stimulated 3-phosphorylated phosphoinositide accumulation is 10 nrnoVLz4 and that for inhibiting pleckstrin phosphorylation is similar. Synthetic PtdIns(3,4,5)P3, when added to saponin-permeabilized (but not intact) platelets, causes worhnannininsensitive phosphorylation of pleckstrin. PtdIns(3,4,5)P3 also overcomes the inhibition by wortmannin of thrombin-or GTPyS-stimulated pleckstrin phosphorylati~n.~~ In contrast, PtdIns(4,5)PZ or Ins(1,3,4,5)P4 is ineffective in these respects. The pattern of phosphorylation of pleckstrin activated by PtdIns(3,4,5)P3 is not distinguishable from that of pleckstrin phosphorylated in intact platelets exposed to PKC-activating P-PMA. These findings implicate a PtdIns(3,4,5)P3-activated protein kinase in pleckstrin phosphorylation, rather than the intrinsic protein kinase activity of PI 3-K. Our findings have been confirmed and extended to PtdIns(3,4)P2, which has also been found to promote pleckstrin phosphorylation, but appears to be less potent than PtdIn~ (Fig   4) thus offers an alternate route to that provided by the activation of PIC, formation of diacylglycerol, and activation of PKC (Fig 3, pathway 6 ; and Fig 4) . This may serve a redundant function, allowing, eg, a PIC deficiency to have less severe consequences for protein phosphorylation under certain circumstances; it may affect the duration of the PKC response, permitting a more sustained activation after diacylglycerol is metabolized; or it may be relevant to the localization of PKC activation. Furthermore, the localized phosphorylation of pleckstrin, near activated PI 3-Ky, may cause a feedback inhibition of PI 3-Ky-mediated production of PtdIns(3,4,5)P3. PI(3,4,5)P3 formed by PI 3-Ky also potentially could compete with phospho-tyrosines for p85PI 3-K, and, in this setting, inhibition of PI 3-Ky by phosphopleckstrin might relieve the inhibition by PI(3,4,5)P3 (due to Activation of (Y/~&'~. Before its recognition as a PI 3-K inhibitor, wortmannin was described as an inhibitor of p-PMA-induced platelet aggregati~n.'~ Furthermore, p85PI 3-K in neutrophils has been reported to be more sensitive to wortmannin than is PI Because we have been interested in the role of the two PI 3-Ks in regulating the conversion of the platelet integrin (Y[lb,& during platelet activation to a form that is competent to bind fibrin~gen,'~.'~ a process often referred to as inside-out signaling, we investigated the relative inhibitory effects of wortmannin on all& activation induced by stimulation of the thrombin receptor or by p-PMA." As a control, we studied the effects of wortmannin on induction of (Y& binding function by anti-LIBS6 Fab (outside-in signaling). We observed that wortmannin (up to 100 nmol/L) does not inhibit the synthesis in intact platelets of PtdIns(4)P, PtdIns(4,5)P2, PtdOH, or the activation of PIC,27 whereas 100 nmol/L wortmannin completely inhibits 3-PPI accumulation in response either to thrombin or p-
in platelets is more sensitive to wortmannin (ICso = 1.3 nmoVL) than is SFLLRN-or thrombin-stimulated 3-PPI accumulation (IC50 = 10 nmol/L), and the activity of p85PI 3-K in immunoprecipitates or in cytoskeletal fractions is inhibited more potently by exposure of platelets to wortmannin than is the activity of PI 3-Ky. The addition of either 0-PMA or SFLLRN to platelets promotes the conversion of (Yl& into a fibrinogen-binding form required for platelet aggregation (Fig 4) , which can be monitored with the fluorescently labeled antibody, PAC1. The PAC1-detectable activation of (Yl& in response to P-PMA or SFLLRN is inhibited by wortmannin with an IC5n of 1 nmol/L in each case, resulting in a maximum inhibition of 50% to 60%. Wortmannin inhibits neither activation of (Yl& by anti-LIBS6 Fab nor anti-LIBS6 Fab-induced platelet aggregation in the presence of fibrinogen, indicating that this type of outside-in signaling by (Yl& is largely PI 3-K-inde~endent.'~ The inhibition of PI 3-K (and aggregation) by wortmannin or an unrelated synthetic compound, LY294002, impairs neither actin polymerization nor secretion. 67 Wortmannin has been shown to inactivate the catalytic p1 IOU subunit of p85PI 3-K by covalently modifying it at LysRo2, which is a residue involved in phosphate transfer by this enzyme." If the concentration of wortmannin is maintained below millimolar levels, there is apparently no direct inhibition of other kinases, such as PKC94; CAMP-dependent, cGMP-dependent, or calmodulin-dependent protein kinasesy6; tyrosine kinase97; or mitogen-activated protein kin a~e .~' It has also been observed that these amounts of wortmannin do not affect resting levels of PtdIns(4)P or PtdIns(4,5)P2 in intact cell^:^,'^ although at higher concentrations a form of membrane-associated PtdIns 4-kinase is inhibited.'" Another target of low nanomolar concentrations of wortmannin is phospholipase A2r102 an enzyme that is not stimulated in platelets exposed to pPMA.'03 Based on these observations, it seems most likely that, under our incubation conditions, wortmannin is specifically targeting PI 3-K and thereby inhibiting platelet aggregation; furthermore, p85PI 3-K, in preference to PI 3-Ky, contributes to the activation of (Y& when the thrombin receptor or PKC is stimulated (Fig 4) . It is not clear what regulates the remaining 40% to 50% of wortmannin-insensitive aggregation, although, in the case of thrombin-induced activation, generation of PtdOH may contribute.'" A similar discrepancy between PI 3-K activity and aggregation with respect to susceptibility to wortmannin is observable when LPA is the agonist, ie, the aggregation response is inhibited by lower amounts of wortmannin than is full production of 3-PPI.'6 It is thus probable that LPA activates both p85PI 3-K and PI 3-Ky and, as for thrombin-activated platelets, that the former is responsible for promoting platelet aggregation, even though both PI 3-Ks appear in the Triton-insoluble cytoskeletal fraction after platelet activation. It seems likely that these differences reflect different microenvironments for activated PI 3-Ks and all& on the platelets' cytoskeletal scaffolding.
CHRF-288 cells: proliferation and morphology. We have also studied thrombin-stimulated morphologic changes and the activation of PI 3-K in CHRF-288 cells.'' We observed that these cells, when exposed to thrombin or SFLLRN, rapidly change shape, forming membrane blebs detectable by differential interference contrast or confocal microscopy as well as radiolabeled (32P-or ['HI-myoinositol) PtdIns(3,4,5)P3 and PtdIns(3,4)P2. The blebs are distinguishable from ruffles or lamellae because they do not contain phalloidin-detectable actin.
Studies with permeabilized CHRF-288 indicate that PI 3-K is activated synergistically by thrombin + GTPyS. Two forms of PI 3-K, ie, PI 3-Ky and p85/PI 3-K, regulated by P y subunits and Rho, respectively, are present in these cells, as is true for platelets. Wortmannin inhibits thrombin-stimulated 3-PPI accumulation in a dose-dependent manner (ICsO = -10 nmol/L) without affecting PIC activation. Pretreatment of CHRF-288 cells with either wortmannin (100 nmol/L) or an unrelated synthetic PI 3-K inhibitor, LY294002 (50 mmolPL), abolishes thrombin receptor-stimulated blebbing. These results suggest that thrombin receptor-stimulated accumulation of 3-PPI ( S ) is required for the shape change response in CHRF-288 cells. LPA and serum are two other agonists for 3-PPI accumulation in CHRF-288 cells, neither of which causes membrane blebbing." However, unlike stimulation of CHRF by thrombin or LPA, stimulation by serum promotes proliferation of these cells, and such proliferation is inhibited by wortmannin (ICso = 15 to 20 nmol/L), implying that PI 3-K activity is necessary, but not sufficient, for agonist-stimulated cell growth or shape change. Additional factors may include the type and localization of PI 3-K activated in response to a given agonist.
CONCLUSION
The preceding findings indicate that PtdIns(4,5)P2, a quantitatively minor lipid in the plasma membrane, acts uniquely as the precursor for three ubiquitous signaling compounds: Ins(1,4,5)P3, DC, and PtdIns(3,4,5)P3 (Fig 3, pathways 1  and 6; and Fig 4) . Much attention has been devoted in the last 10 years to the mode of action of the first two second messengers. It is clear that the focus will now be on the third, as well as on PtdIns(3,4)Pz, a possible metabolite of For personal use only. on October 31, 2017. by guest www.bloodjournal.org From PtdIns(3,4,5)P3 in vivo (Fig 3, pathway 4) . Because synthetic 3-PPIs have become available recently, such studies have become much more feasible. With respect to potential targets for PtdIns(3,4,5)P3, the proposal of Downes and CarterJ4 seems the most likely, ie, rather than, for example, interacting stoichiometrically with cytoskeletal proteins, PtdIns(3,4,5)P3 would be more effective as a modulator of the activity of an enzyme, such as a kinase, that can amplify its signal. Studies with PKCs make this proposal increasingly p l a~s i b l e . *~~~* *~~ Conceivably, 3-PPIs might modulate a tyrosine kinase (or phosphatase) or some other enzyme activity. Numerous questions remain. Is PtdIns(3,4)P2 synthesized by PtdIns(4)P 3-K, PtdIns(3)P 4-K, andfor by hydrolysis of PtdIns(3,4,5)P3 (Fig 2) ? Why is its synthesis delayed? Our studies with phospho-pleckstrin indicate circumstances in which PI 3-Ky acting on PtdIns(4,5)P2 would be inhibited, whereas PI 3-Ky acting on PtdIns(4)P would not. Furthermore, PtdIns(3,4,5)P3, rather than PtdIns(3,4)P2, can inhibit binding of p85PI 3-K to phospho-tyrosines"; this also might favor p85PI 3-K action on PI(4)P, because the product of that activity, PtdIns(3,4)P2, would not impair localization of p85PI 3-K and its further activity. Why is accumulation of PtdIns(3,4)P2 potentiated by occupancy of al&? Does PtdIns(3,4)P2 have its own signaling targets, apart from those of PtdIns(3,4,5)P3? Can PtdIns(3,4)P2 act as an antagonist of PtdIns(3,4,5)P3 effects? Of course, the regulation of the activity of p85PI 3-K is a major subject for experimental inquiry. How do Rho and PKC exert their effects in stimulating p85PI 3-K? How might CDC42Hs, another Rho-family small G-protein present in platelet^'^ that is not ADP-ribosylatable but is known to bind recombinant p85PI 3-K and activate it,Ifl5 be involved in regulating platelet p85PI 3-K? How is Rho activated in response to platelet agonists? How many philin modules, in addition to SH2, SH3, and PH, are involved in targeting and activating PI 3-Ks? How does p85/ PI 3-K promote activation of platelet integrin a,&? What is the function of PI 3-Ky? Where are p85/PI 3-K versus PI 3-Ky localized on the activated platelet's cytoskeletal scaffolding, allowing selective effects on alp,P3? What other PI 3-Ks are present in platelets andlor platelet progenitor cells, and what functions do they perform? We have indications, for example, of at least two forms, in addition to pllOa, pllOp, and pllOy (and p85a and p), of PI 3-K in platelets and CHRF-288 cells (SE. Rittenhouse and S . Volinia, unpublished results). One of the two isoforms is most likely a VPS34-type PtdIns 3-kinase,'" whereas the other (thus far designated PI 3-Kq S.E. Rittenhouse and S . Volinia, unpublished results) bears some resemblance to new PI 3-Ks called p170"" and Cpk."' It seems likely that this latest chapter in the story of phosphoinositide metabolism's role in signal transduction will yield surprises at least equal to those encountered earlier. Clark 
SS.
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